US regulator allows GSK’s endometrial cancer therapy for expanded use
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
HQ Team May 9, 2024: Merck announced that its Phase 3 trial evaluating Keytruda therapy in combination with chemotherapy, with or without radiotherapy,.
HQ Team October 30, 2023: GSK plc has announced significant findings from a phase III trial trial for Jemperli (dostarlimab), a potential treatment for.
HQ Team October 5, 2023: A new study by Columbia University Mailman School of Public Health and NYU Grossman School of Medicine says.